BACKGROUND: Glycemic variability has been proposed as a contributing factor in the development of diabetes complications. Multiple measures exist to calculate the magnitude of glycemic variability, but normative ranges for subjects without diabetes have not been described. For treatment targets and clinical research we present normative ranges for published measures of glycemic variability. METHODS: Seventy-eight subjects without diabetes having a fasting plasma glucose of <120 mg/dL (6.7 mmol/L) underwent up to 72 h of continuous glucose monitoring (CGM) with a Medtronic Minimed (Northridge, CA) CGMS(®) Gold device. Glycemic variability was calculated using EasyGV(©) software (available free for non-commercial use at www.easygv.co.uk ), a ...
Background The validity of continuous glucose monitoring (CGM) is well established in diabetic patie...
The routine approach to evaluating the effectiveness of diabetes treatment based on the level of gly...
Authors and colleagues have continued clinical diabetic research in the light of Continuous Glucose ...
Background: Glycemic variability has been proposed as a contributing factor in the development of di...
Aims: While there has been much debate about the clinical importance of glycemic variation (GV), lit...
The validity of continuous glucose monitoring (CGM) is well established in diabetic patients. CGM is...
Near normal glycaemic control in diabetes consists to target daily glucose fluctuations and quarterl...
International audienceThe assessment of glycaemic variability (GV) remains a subject of debate with ...
International audienceGlycemic variability (GV) appears today as an integral component of glucose ho...
Objective: To report the impact of continuous glucose monitoring (CGM) on glycemic variability (GV) ...
<div><p>Background</p><p>The validity of continuous glucose monitoring (CGM) is well established in ...
International audienceOBJECTIVE:To define the threshold for excess glucose variability (GV), one of ...
The dysglycemia of diabetes includes two components: (1) sustained chronic hyperglycemia that exerts...
Objective: Glycemic variability (GV) is an important component of overall glycemic control for patie...
HbA1c reflects average glucose levels over 3 months, but it does not measure glycemic variability. T...
Background The validity of continuous glucose monitoring (CGM) is well established in diabetic patie...
The routine approach to evaluating the effectiveness of diabetes treatment based on the level of gly...
Authors and colleagues have continued clinical diabetic research in the light of Continuous Glucose ...
Background: Glycemic variability has been proposed as a contributing factor in the development of di...
Aims: While there has been much debate about the clinical importance of glycemic variation (GV), lit...
The validity of continuous glucose monitoring (CGM) is well established in diabetic patients. CGM is...
Near normal glycaemic control in diabetes consists to target daily glucose fluctuations and quarterl...
International audienceThe assessment of glycaemic variability (GV) remains a subject of debate with ...
International audienceGlycemic variability (GV) appears today as an integral component of glucose ho...
Objective: To report the impact of continuous glucose monitoring (CGM) on glycemic variability (GV) ...
<div><p>Background</p><p>The validity of continuous glucose monitoring (CGM) is well established in ...
International audienceOBJECTIVE:To define the threshold for excess glucose variability (GV), one of ...
The dysglycemia of diabetes includes two components: (1) sustained chronic hyperglycemia that exerts...
Objective: Glycemic variability (GV) is an important component of overall glycemic control for patie...
HbA1c reflects average glucose levels over 3 months, but it does not measure glycemic variability. T...
Background The validity of continuous glucose monitoring (CGM) is well established in diabetic patie...
The routine approach to evaluating the effectiveness of diabetes treatment based on the level of gly...
Authors and colleagues have continued clinical diabetic research in the light of Continuous Glucose ...